CorMedix to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CorMedix (Nasdaq: CRMD) said senior management will present and meet investors at three healthcare conferences in March 2026: Leerink Partners (March 10), Citizens Life Sciences (March 11) and Barclays (March 12).

The company listed formats (fireside chats and one-on-one meetings) and webcast links where available for investor access.

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March.

Leerink Partners Global Healthcare Conference
Date:		March 10, 2026
Time:		1:00pm Eastern
Format:		Fireside Chat
Webcast:		Link to webcast
Citizens Life Sciences Conference
Date:		March 11, 2026
Time:		9:35am Eastern
Format:		Fireside Chat
Webcast:		Link to webcast
Barclays 28th Annual Global Healthcare Conference
Date:		March 12, 2026
Format:		One-on-one investor meetings

About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath^® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN^® (minocycline) for Injection, REZZAYO^® (rezafungin for injection), VABOMERE^® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA^® (delafloxacin), and KIMYRSA^® (oritavancin), as well as TOPROL-XL^® (metoprolol succinate).

CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

FAQ

When will CorMedix (CRMD) present at the Leerink Partners Global Healthcare Conference in 2026?

CorMedix will present on March 10, 2026 at 1:00pm Eastern in a fireside chat format. According to the company, the event includes a webcast link for investors to watch the presentation live or on demand.

What is the schedule for CorMedix (CRMD) at the Citizens Life Sciences Conference in March 2026?

CorMedix is scheduled for a fireside chat on March 11, 2026 at 9:35am Eastern. According to the company, management will present and a webcast link will be provided for investor access.

Will CorMedix (CRMD) hold one-on-one meetings at the Barclays Global Healthcare Conference in March 2026?

Yes. CorMedix plans one-on-one investor meetings at the Barclays 28th Annual Global Healthcare Conference on March 12, 2026. According to the company, senior management will participate in bilateral investor sessions.

How can investors watch CorMedix (CRMD) presentations at the March 2026 conferences?

Investors can access available presentations via provided webcasts and links for the March events. According to the company, webcast links are listed for the Leerink and Citizens conference sessions for live or archived viewing.

What should shareholders expect from CorMedix (CRMD) at the March 2026 investor events?

Shareholders should expect executive presentations and investor meetings focused on company updates and strategy in March 2026. According to the company, senior management will present in fireside chats and hold one-on-one investor meetings.